Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting.

MLA

Körner, Meike, et al. “Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for in Vivo Somatostatin Receptor Targeting.” The American Journal of Surgical Pathology, vol. 36, no. 2, Feb. 2012, pp. 242–52. EBSCOhost, https://doi.org/10.1097/PAS.0b013e31823d07f3.

APA

Körner, M., Waser, B., Schonbrunn, A., Perren, A., & Reubi, J. C. (2012). Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. The American Journal of Surgical Pathology, 36(2), 242–252. https://doi.org/10.1097/PAS.0b013e31823d07f3

Chicago

Körner, Meike, Beatrice Waser, Agnes Schonbrunn, Aurel Perren, and Jean Claude Reubi. 2012. “Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for in Vivo Somatostatin Receptor Targeting.” The American Journal of Surgical Pathology 36 (2): 242–52. doi:10.1097/PAS.0b013e31823d07f3.